

3M Internal Correspondence

TO: S. M. LEAHY - EXECUTIVE - 220-13E-33

FROM: C. W. OLSON - CF&AP GROUP COMPLIANCE - 236-GL-04

SUBJECT: Fluorochemical Steering Committee Minutes

DATE: July 22, 1992

The Fluorochemical Steering Committee met July 21, 1992. A copy of the agenda is attached. Upon the recommendation of the July 16 committee meeting new members added were Carol Bros, Group General Counsel, and Don Theissen, Director, Corporate Product Responsibility. My letter to you of June 5, 1992, with respect to the recommendations from the FCSC May 26, 1992 meeting were reviewed.

The purpose of this meeting was to update the FCSC on current issues and to develop recommendations for future actions. Guests present included Dr. Frank Gilliland and Dr. Jeff Mandel from Occupational Medicine, Dr. C. D. Hodgson, Corporate Medical Director, Jim Wolter, Jim Johnson, and Robert Howell from Environmental Engineering and Roger Perkins, Toxicology.

The following summaries were presented. Roger Perkins, Corporate Toxicology pointed out that a great deal of activity is occurring outside 3M on fluorochemicals. There have been 32 publications on perfluorodecatonic acid. They also cited additional work on perfluorocarboxylic acid with the rat. There is additional work on perfluorooctonic acid being reported in the literature. This would be pertinent to our FC-143 studies. Griffin Chemicals has sent us toxicity data they have developed on their sulfuramid. This did not contain any two year studies. They did, however, submit a "For Your Information" in which it appears there is more toxicity in some aquatic species in branched fluorochemical than straight chain material.

Dr. Frank Gilliland, a consultant to the Occupational Medicine Department presented information on an epidemiologic study on Chemolite employees. It was pointed out that in hormonal studies such as this measurable changes do not necessarily mean that disease will occur. Results showed that the control group showed more blood fluorine than we would have expected. This may be because of an unknown exposure or could have been caused by improper selection of the control group. Changes in testosterone were age and weight related.

Trial Exhibit 3214

3MA00638323

**Exhibit
2725**

State of Minnesota v. 3M Co.,
Court File No. 27-CV-10-28862

3M_MN00000789

2725.0001

A cohort mortality study which showed no excess mortality was reported. In other words, death was less than the general population. This may have been because of low incidence of cardiovascular diseases. When the length of service versus prostate cancer mortality was looked at the value of 3.0 was higher than expected but still not significant. 744 workers were studied and no major mortality excesses were present.

Jim Johnson, EE&PC Laboratory, reported on the analytical work to date. FC-95 and FC-143 are being primarily looked at. Negative ion thermal spray has been used and he is able to detect levels at 50 ppm in water or acrylonitrile. Lactating goats have been dosed and also bovine serum obtained to develop spiked sample references. Additional equipment is on order and work is planned.

Roger Perkins, Toxicology Services, reported that on work we have done by outside laboratories we are using Good Laboratory Practices. Because our work will require extensive review the question of GLP procedures for 3M internal laboratory procedures was discussed.

Following the general meeting a separate meeting of fluorochemical steering committee members and Dr. Hodgson was held. The principal discussion centered around the creation of a technical sub-committee to provide guidance for the steering committee on technical matters. The following subjects were considered for review by the technical sub-committee.

- Prioritize potential applications for risk and the compounds related to them.
- Relationship between exposure and blood fluorine levels. This would include the skin versus the other types.
- Sampling and analytical exposure sampling techniques and recommendations for methods to be used.
- A common approach to safety, health and environmental issues.
- Collection and sharing of technical information related to safety, health and environmental issues and fluorochemicals.
- Collection and sharing of safety, health and environmental information related to fluorochemicals.
- Research directions for new fluorochemical materials.
- Basic pharmacokinetic metabolism studies.

3MA00638324

3M_MN00000790

A discussion followed which centered around the membership of this technical committee. Initial members to be considered included Roger Perkins from Toxicology, Stan Sorenson from Industrial Hygiene, Jim Johnson from the EE&PC Laboratory, Robert Howells from EE&PC, Drs. Jeff Mandel and Frank Gilliland from Occupational Medicine, Dr. V. from SA&CD Analytical Laboratories, Don James or John Marhevka from Central Research Analytical Services and chairing the committee, Craig Burton from the Fluorochemical Technology Center.

The following actions will be taken:

1. Jim Johnson will continue his work on the development of analytical capabilities for fluorochemicals.
2. The Fluorochemical Technology Sub-committee will be named by consensus and Craig Olson will call the first meeting.
3. John Butenhoff, Larry Zoebel, Rick Davis and Georjean Adams will convene to determine whether the data presented by Dr. Gilliland constitutes a TSCA 8(e) submission..
4. The Fluorochemical Steering Committee will be reconvened as soon as appropriate to address the current priority issues.



CWO:mms

dc: Dale Bacon	2-3E-09
Robert Bringer	21-2E-07
Carol Bros	220-11E-03
John Butenhoff	220-2E-02
Frank Gilliland	220-2E-02
Jim Johnson	2-3E-09
Jeff Mandel	220-2E-02
Roger Perkins	220-2E-02
Tom Savereide	236-1B-21
Jim Sugg	220-2E-02
Don Theissen	225-3N-02
Frank Vikingstad	223-1N-08
Larry Zoebel	220-2E-02

3MA00638325

3M_MN00000791